RESEARCH - CLINICAL TRIALS

Clinical Trials with Nimotuzumab

Nimotuzumab is being investigated in several clinical trials worldwide, focussing on the treatment of EGFR-positive cancers. The monoclonal antibody specifically targets the EGFR receptor (Epidermal Growth Factor Receptor), which is overexpressed in many tumour types, such as head and neck squamous cell carcinoma (HNSCC), glioma and nasopharyngeal carcinoma (NPC). The mechanism of action of nimotuzumab is aimed at slowing tumour growth, inhibiting metastasis and enhancing the immune response against cancer cells.

The key findings from the clinical trials include:

  • Combination therapy: nimotuzumab is being tested in combination with chemotherapy, radiotherapy and immune checkpoint inhibitors to evaluate its potential to enhance the efficacy of these therapies.
  • Safety profile: Studies show that nimotuzumab has a favourable safety profile, with predominantly mild to moderate side effects such as fatigue, rash and fever, which appear less toxic than with conventional chemotherapies.
  • Target group: The trials are primarily aimed at patients with advanced, recurrent or metastatic EGFR-positive tumours, particularly when other treatment options have been insufficiently effective.
Oncoscience GmbH’s commitment to clinical research

As the exclusive licence holder for nimotuzumab in Europe, Oncoscience GmbH is significantly involved in the development and clinical research of this active substance. The company is working closely with leading research institutions, clinics and regulatory authorities to expand the potential applications of nimotuzumab.

A particular focus is on:

  • Supporting clinical research: Oncoscience is actively involved in studies investigating the safety, efficacy and long-term effects of nimotuzumab in oncology.
  • Expansion of indications: The aim is to make innovative treatment options available for patients with rare and difficult-to-treat cancers.
  • Collaboration with healthcare professionals: Through close partnerships with clinicians and researchers, Oncoscience promotes the development of targeted therapies that meet the specific needs of patients.

If you are a healthcare professional looking for more information on clinical trials with nimotuzumab or opportunities to participate in research projects, please contact Oncoscience GmbH directly.